(Yicai Global) Aug. 8 -- China's new anti-corruption campaign targeting medical companies will benefit long-term development, several industry players said after pharmaceutical equities plunged.

Anti-graft measures are necessary to promote the implementation of the Healthy China 2030 strategy while protecting the public interest, multiple drugmakers said to Yicai. The Healthy China 2030 strategy aims to ensure all Chinese people have access to health and proper care.

Shares of almost 150 of the nearly 510 listed healthcare companies in China have dropped for seven days or more, and more than 50 of them have slumped by more than 10 percent after regulators held a conference on July 21 to announce the heightened focus on unfair market behaviors, according to Wind data. Ten out of the 20 biggest capital market losers in the past couple of weeks report sales expenses higher than 30 percent of their revenue.

SL Pharmaceutical believes that most drugmakers hope the campaign will bring equal treatment to companies that stick to fair competition, per the Beijing-based company. If the measures are thorough, the industry will go through a reshuffle, it added.

C.Q. Pharmaceutical Holding told its investors that the campaign will not adversely affect its operations. Anti-corruption is the only way for the industry to return to normal order, benefiting long-term and healthy development, the Chongqing-based firm said.

Mayinglong Pharmaceutical Group agreed that the actions will promote the healthy development of the industry and added that the Wuhan-based firm will never violate any laws or regulations as it seeks sustainable growth.

Anti-corruption is part of the reform of the medical and health system and will promote high-quality development, Bloomage BioTechnology added.

Editor: Emmi Laine